Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
相关临床试验
35
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
已完成
33
94.3%
招募中
1
2.9%
撤回
1
2.9%
暂无批准数据
- A Complete Response Letter (CRL) is the FDA's formal notice that a drug application cannot be approved in its current form, citing deficiencies in safety, efficacy, manufacturing, or labeling. - CRLs can trigger severe market reactions, with single-day stock declines ranging from 2% (AbbVie) to 75% (Aldeyra Therapeutics), depending on the nature and severity of the deficiencies. - Companies can pursue Class 1 resubmissions for minor fixes (approximately two-month review) or Class 2 resubmissions for substantial changes (approximately six-month review), with successful resubmissions enabling significant stock recoveries. - Fortress Biotech's CUTX-101 and Capricor Therapeutics' deramiocel demonstrate that CRLs are not terminal, as both programs advanced toward approval following resubmission.
- Aldeyra Therapeutics faces a securities fraud class action lawsuit for allegedly making misleading statements about reproxalap clinical trial consistency between November 2023 and March 2026. - The FDA issued a Complete Response Letter rejecting reproxalap, determining that clinical results were inconsistent and positive findings were neither reliable nor meaningful. - ALDX shares plummeted 70.7%, losing $2.99 per share to close at $1.24 on March 17, 2026, following the FDA's rejection disclosure. - The lead plaintiff deadline is May 29, 2026, with institutional investors including pension funds and asset managers encouraged to evaluate participation.
- The FDA declined to approve Aldeyra Therapeutics' reproxalap for dry eye disease, marking the company's third consecutive regulatory setback since 2023. - The complete response letter cited insufficient efficacy data while raising no safety or manufacturing concerns for the drug. - Aldeyra shares plunged over 70% in premarket trading following the announcement, with the company planning to request a Type A meeting with the FDA. - The rejection affects treatment options for the 16.4 million Americans living with dry eye disease, a condition causing discomfort and potential vision problems.
- The FDA has extended the PDUFA target action date for Aldeyra Therapeutics' reproxalap New Drug Application for dry eye disease treatment from December 16, 2025, to March 16, 2026. - The extension was triggered by the FDA's request for a Clinical Study Report from a field trial that supported reproxalap's activity but failed to meet its primary endpoint of symptom improvement. - The FDA indicated that if no major deficiencies are identified during the extended review, it plans to communicate proposed labeling requests by February 16, 2026. - Aldeyra's stock declined 12.11% in regular trading and an additional 16.79% in after-hours trading following the announcement.
- A new Q4 2025 Catalyst Monitor report identifies 20 significant market-moving events expected in the fourth quarter, based on key opinion leader interviews and predictive intelligence. - Major approval decisions are anticipated for Cytokinetics' aficamten for obstructive hypertrophic cardiomyopathy and Aldeyra's reproxalap for keratoconjunctivitis sicca. - GSK's depemokimab faces regulatory decisions for chronic rhinosinusitis and asthma, while ongoing trials include Sanofi's tolebrutinib for primary progressive multiple sclerosis. - The report covers trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals across diverse therapeutic areas.
- Aldeyra Therapeutics announced discontinuation of ADX-629 development despite positive Phase II results in alcohol-associated hepatitis, showing significant improvements in liver function markers including MELD score and C-reactive protein levels. - The company is refocusing its pipeline on next-generation RASP modulators ADX-248 and ADX-246, with IND applications planned for 2026 targeting metabolic inflammation and dry age-related macular degeneration respectively. - The strategic realignment extends Aldeyra's operational runway into the second half of 2027, while maintaining its late-stage programs in dry eye disease and other ophthalmic conditions. - Following initial stock volatility, shares recovered to close at $5.14, maintaining the company's market capitalization at approximately $308.6 million.
- The FDA published more than 200 Complete Response Letters (CRLs) from 2020-2024 for drug applications that were initially rejected but later approved, marking a significant step toward increased regulatory transparency. - Commissioner Marty Makary stated that drug developers have been "playing a guessing game" with FDA navigation, emphasizing the need for greater predictability in the approval process. - The initiative addresses a longstanding issue where sponsors historically avoided mentioning 85% of FDA safety and efficacy concerns when publicly announcing rejections, according to a 2015 FDA analysis. - The letters are now accessible through openFDA, the first centralized database of past CRLs, with redactions for trade secrets and confidential commercial information.
- The FDA has accepted Aldeyra Therapeutics' New Drug Application (NDA) for reproxalap, a topical ocular therapy for dry eye disease, with a PDUFA date of April 2, 2025. - Reproxalap, a first-in-class RASP modulator, has demonstrated significant clinical efficacy and safety in reducing the signs and symptoms of dry eye disease in multiple late-stage trials. - Aldeyra has expanded its collaboration with AbbVie to accelerate pre-commercial activities, with AbbVie covering 60% of the costs and a potential $100 million upfront payment upon exercising its option. - The partnership includes up to $300 million in milestone payments and a profit-sharing model for U.S. commercialization, positioning reproxalap as a potential game-changer in dry eye disease treatment.
- The FDA issued a Complete Response Letter for Astellas Pharma's avacincaptad pegol intravitreal solution, indicating the sNDA cannot be approved in its current form. - Aldeyra Therapeutics' resubmitted NDA for topical ocular reproxalap, a first-in-class investigational candidate for dry eye disease, has been accepted by the FDA. - Aldeyra Therapeutics is expanding its option agreement with AbbVie, securing additional funding to support the commercialization of reproxalap. - Ocular imaging in emergency departments, utilizing non-mydriatic fundus cameras, enhances timely and accurate diagnoses, benefiting both patients and on-call ophthalmologists.
- The FDA issued a Complete Response Letter for Astellas' IZERVAY (avacincaptad pegol) due to a statistical matter regarding proposed labeling language, unrelated to safety or efficacy. - Aldeyra Therapeutics' resubmitted New Drug Application (NDA) for reproxalap, a topical ocular treatment for dry eye disease, has been accepted by the FDA. - Aldeyra Therapeutics is expanding its option agreement with AbbVie, providing additional funding to support the commercialization of reproxalap for dry eye.
